Moxifloxacin

Mycoplasma genitalium

Sexually active

Biology

Chlamydia trachomatis

Virology

Biochemistry

Genetics

Minimum inhibitory concentration

Broth microdilution

Minocycline

Mycoplasma

Doxycycline

In vitro

Human immunodeficiency virus (HIV)

Antibiotics

Microbiology

Internal medicine

Pharmacology

Gynecology

Medicine

Chemistry

Azithromycin

Genitourinary system

Tetracycline

Microbiology Spectrum

Here, we performed in vitro susceptibility testing on 10 Mycoplasma genitalium isolates against omadacycline, minocycline, tetracycline, doxycycline, moxifloxacin, levofloxacin, and azithromycin. Omadacycline was the most potent agent, with all MICs of ≤0.5 μg/mL. MICs were not affected by resistance to other agents, including resistance to other tetracycline class drugs. Omadacycline may be a potential treatment option for M. genitalium infection. IMPORTANCE There are very few clinical isolates of Mycoplasma genitalium available for in vitro susceptibility testing. We studied 10 isolates and determined that the new semisynthetic aminomethylcycline omadacycline is active against isolates that are resistant to tetracyclines, macrolides, and quinolones. These data suggest that clinical studies should be performed in order to see if omadacycline may be useful to treat urogenital infections caused by M. genitalium.

Omadacycline Is Highly Active <i>In Vitro</i> against Mycoplasma genitalium

Omadacycline Is Highly Active In Vitro against Mycoplasma genitalium